Medpace Holdings, Inc. (MEDP) stock: key figures, P/E, revenue and dividend

Industrials · United States · ISIN US58506Q1094

Price

616.63 USD

Market cap

17.21 bn USD

P/E (2026)

–

P/S (2026)

–

Dividend yield

0.00 %

Net margin

–

Return on equity (ROE)

–

Return on assets (ROA)

–

Medpace Holdings, Inc. financials

Fiscal year	2025
Revenue	2.53 bn USD
Operating income	534.94 m USD
EBIT	542.38 m USD
Net income	451.12 m USD
Diluted EPS – continuing operations	15.28 USD

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.